Teva accuses Corcept, Optime of blocking generic competition for Cushing’s treatment
MLex Summary: Teva Pharmaceuticals filed a US antitrust complaint accusing Corcept Therapeutics and Optime Care of illegally blocking generic competition for Corcept’s branded drug Korlym, a treatment for Cushing’s disease. According to...To view the full article, register now.
Already a subscriber? Click here to view full article